Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount | Activity | Investigator |
Unit |
Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Prescribing Vitamin D: An Exploratory Comparative Survey of University of Arizona Integrative Medicine Fellows' Attitudes and Practices | Contract | $101,919.00 | Research | Lisa Alschuler | Andrew Weil Ctr Intgrtv Med | Pharmavite | 01/2020 |
| Coronavirus Telehealth Resource Centers | Grant | $828,571.00 | Other Sponsored Activity | Ronald Weinstein | Arizona Telemedicine Program | Health Resources and Services Administration | 06/2020 |
| A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 with Placebo and with Tofacitinib in Combination with Conventional Synthetic DMARDs.... | Contract | $314,050.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | IQVIA RDS Inc. | 03/2020 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated... | Contract | $55,928.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | Cumberland Pharmaceuticals, Incorporated | 07/2020 |
| Binational Early Asthma & Microbiome Study (BEAMS) | Grant | $15,309,471.00 | Research | Fernando Martinez | Asthma/Airway Disease Rsch Ctr | National Institute of Allergy and Infectious Disease | 08/2020 |
| Epitope Open-Label Extension Study to Evaluate the Long-Term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) | Contract | $173,290.72 | Clinical Trial | Heather Cassell | Asthma/Airway Disease Rsch Ctr | Pharmaceutical Research Associates | 02/2020 |
| A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses.... | Contract | $273,767.50 | Clinical Trial | Cori Daines | Asthma/Airway Disease Rsch Ctr | Janssen Research & Development, LLC | 01/2020 |
| Octapharma's Octagam 10% Gam10-09 Study | Contract | $64,944.00 | Research | Michael Daines | Asthma/Airway Disease Rsch Ctr | Octapharma Pharmazeutika Produktionsgesellschaft mbH (Austria) | 08/2020 |
| B Cell-Adaptive Immune Profile in Emphysema-Predominant COPD | Grant | $3,364,046.00 | Research | Francesca Polverino | Asthma/Airway Disease Rsch Ctr | National Heart, Lung, and Blood Institute | 07/2020 |
| Early Origins of Chronic Lung Disease: Outcomes into the Fifth Decade of Life | Grant | $6,030,330.00 | Research | Fernando Martinez | Asthma/Airway Disease Rsch Ctr | National Heart, Lung, and Blood Institute | 04/2020 |
| Beyond Pseudotime: Enhanced Single-cell GEnomics Tools for Understanding the Temporal Dynamics of Development and Disease | Grant | $1,822,950.00 | Research | Darren Cusanovich | Asthma/Airway Disease Rsch Ctr | National Institute of General Medical Sciences | 08/2020 |
| Area Health Education Centers Program COVID | Grant | $95,455.00 | Instruction | Daniel Derksen | AZ Health Education Centers | Health Resources and Services Administration | 06/2020 |
| Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer w | Contract | $100,897.00 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Phoenix Molecular Designs (Canada) | 02/2020 |
| SWOG NCORP Research Base | Cooperative Agreement | $54,000.00 | Clinical Trial | Daniel Persky | Cancer Center Division | Oregon Health and Science University | 07/2020 |
| Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer | Cooperative Agreement | $64,679.91 | Research | Denise Roe | Cancer Center Division | Beckman Research Institute of The City of Hope | 03/2020 |
| A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | Contract | $91,617.50 | Clinical Trial | Pavani Chalasani | Cancer Center Division | Zeno Pharmaceuticals, Inc. | 01/2020 |
| A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors | Contract | $458,027.74 | Clinical Trial | Hani Babiker | Cancer Center Division | Parexel International Corporation | 01/2020 |
| NRG Oncology NCORP Research Base | Cooperative Agreement | $144,704.00 | Research | Cynthia Thomson | Cancer Center Division | NRG Oncology | 05/2020 |
| Aberrant DNA Repair and Lupus | Grant | $6,175,318.00 | Research | Joann Sweasy | Cancer Center Division | National Institute of Environmental Health Sciences | 07/2020 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Efficacy and Safety of Anamorelin HCL for the Treatment OF Malignancy Associated Weight Loss and Anorexia... | Contract | $42,626.00 | Clinical Trial | Charles Hsu | Cancer Center Division | PSI Pharma Support America, Incorporated | 01/2020 |
| Structure and Function of DNA Repair Enzymes and Cancer | Grant | $487,283.00 | Research | Joann Sweasy | Cancer Center Division | University of Vermont | 03/2020 |
| A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors | Contract | $513,891.00 | Clinical Trial | Montaser Shaheen | Cancer Center Division | Ascentage Pharma | 01/2020 |
| The Role of an MSH6 Gene Variant and UV Radiation in Systemic Lupus Erythematosus | Grant | $174,926.00 | Research | Rithy Meas | Cancer Center Division | National Institute of Environmental Health Sciences | 08/2020 |
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel.. | Contract | $327,830.00 | Clinical Trial | Abhijeet Kumar | Cancer Center Division | Covance, Incorporated | 01/2020 |
| A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... | Contract | $100,897.00 | Clinical Trial | Setsuko Chambers | Cancer Center Division | GOG Foundation, Inc. | 08/2020 |